Bridges, Ian
Amgen (United Kingdom)
2 papers on CoChatORCID 0000-0002-3317-3528
Most cited papers
- Verified
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
Raal, F. J., Stein, E. A., Dufour, R., Turner, T., Civeira, F., Burgess, L., Langslet, G., Scott, R., Olsson, A. G., Sullivan, D., et al. (2015) · The Lancet
Lipoproteins and Cardiovascular HealthLipid metabolism and disorders
Cited by 756
- Verified
Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia
Rosenson, R. S., Jacobson, T. A., Preiss, D., Djedjos, C. S., Dent, R., Bridges, I., & Miller, M. (2016) · Cardiovascular Drugs and Therapy
Lipoproteins and Cardiovascular HealthLipid metabolism and disorders
Cited by 36
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free